Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CTBP1
REST API REST API
Homo sapiens
CTBP1 is differentially expressed in 312 experiments: 134 organism parts: cerebellum, bone marrow, ... (132 more);, 199 disease states: normal, control, ... (197 more);, 85 cell types 400 cell lines 35 compound treatments and 83 other conditions.
Synonyms BARS
Orthologs F6V944_CIOIN (Ciona intestinalis)   A5D9F1_BOVIN (Bos taurus)   Ctbp1 (Mus musculus)   Ctbp1 (Rattus norvegicus)   CtBP (Drosophila melanogaster)   SER3 (Saccharomyces cerevisiae)   SER33 (Saccharomyces cerevisiae)   CTBP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term oxidoreductase activity, transcriptional repressor complex, cofactor binding, negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, negative regulation of cell proliferation, transcription, DNA-dependent, metabolic process, protein domain specific binding, transcription factor binding, cell differentiation, regulation of cell cycle, nucleus, oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor, phosphogluconate dehydrogenase (decarboxylating) activity, pentose-phosphate shunt, transcription factor complex, binding, protein C-terminus binding, negative regulation of transcription from RNA polymerase II promoter, NAD binding, negative regulation of histone acetylation, interspecies interaction between organisms, regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor, viral genome replication, positive regulation of histone deacetylation, white fat cell differentiation, oxidation-reduction process, sequence-specific DNA binding transcription factor activity, protein phosphorylation, negative regulation of histone H4 acetylation, regulation of transcription by chromatin organization
InterPro Term D-isomer_2_OHA_DH_NAD-bd, D-isomer_2_OHA_DH_cat_dom, 6PGDH_NADP-bd
UniProt Accession Q13363, D6RAX2, Q9NSY3, Q7Z2Q5, E7EPF8, E7ESU7, E7EUB3, E9PGB1
Search EB-eye ENSG00000159692
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-22541, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-5823, E-GEOD-3529, E-GEOD-20081
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
HL-60
2
E-GEOD-24147, E-GEOD-5258
BT20
2
E-MTAB-62, E-MTAB-37
BT-474
2
E-GEOD-3529, E-GEOD-5823
DU145
2
E-GEOD-17482, E-GEOD-20089
394 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-4219, E-GEOD-20677, E-GEOD-13909, ... (36 experiments)

Factor Value U/D Experiments
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
mononuclear
2
E-GEOD-13987, E-GEOD-26672
intraepithelial cytotoxic T lymphocyte
1
E-GEOD-4592
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
granulopoietic
1
E-GEOD-9894
human embryonic stem cell
1
E-GEOD-20033
79 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-12254, ... (67 experiments)

Factor Value U/D Experiments
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
dermatomyositis
2
E-GEOD-5370, E-MTAB-62
Burkitt's lymphoma
2
E-GEOD-1880, E-GEOD-96
astrocytoma
2
E-MTAB-37, E-GEOD-4290
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
lung adenocarcinoma
2
E-MTAB-37, E-MEXP-231
193 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-12438, E-GEOD-3720, E-GEOD-5824, ... (21 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
none
2
4
E-GEOD-5824, E-MEXP-1958, E-GEOD-412, E-TABM-868, E-GEOD-995, ... (6 experiments)
control
2
E-GEOD-995, E-GEOD-3284
bacterial endotoxin
1
E-GEOD-3284
cigarette smoke
1
E-TABM-127
sapphyrin PCI-2050
1
E-GEOD-6400
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (10 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-GEOD-20847, E-GEOD-6431, E-GEOD-4006 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-MEXP-1437, E-GEOD-2466, E-GEOD-17476, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-GEOD-9593, E-MEXP-1648, ... (51 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-6434, E-GEOD-1657 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-1643, E-GEOD-19743, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307, ... (6 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-22541, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.372 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM